指南与共识临床试验与 GCP

临床试验导入期用药依从性测量、分析与报告指南(MARMAR)

Guideline for the Measurement, Analysis and Reporting of Medication Adherence during the Run-in phase of clinical trials (MARMAR).
指南 / 共识 · Trials · 2026-04-16

MARMAR 指南通过系统综述生成初始条目,经两轮改良德尔菲调查国际专家并达成共识,最终形成 20 条条目(9 条方法学、11 条报告),旨在规范临床试验导入期用药依从性的测量、分析与报告,提升试验透明度与严谨性。

要点

  • MARMAR 指南包含 9 条方法学条目和 11 条报告条目,用于规范导入期用药依从性管理。
  • 指南由 ESPACOMP 认可并在 EQUATOR 注册,基于两轮改良德尔菲专家共识制定。
  • 应用该指南可提高未来临床试验导入期测量、分析与报告的透明度和严谨性。

核心结论

  • MARMAR 指南是首个专门针对临床试验导入期用药依从性的结构化共识指南,有助于改善未来试验导入期的质量。

研究设计与样本

  • 基于系统综述生成初始条目,经试点修订后开展两轮改良德尔菲调查(第一轮 49 名专家评 29 条,第二轮 27 名专家评 20 条修订条目),最终经研究团队共识会议定稿。

主要发现

  • 第一轮中 64-100%(均值 86.5%)的专家对条目评分为 4 或 5,28 条达成共识,226 条自由文本评论导致条目合并。
  • 第二轮中 33-100%(均值 78.7%)的专家将修订条目评为必需,并收集 66 条自由文本评论。
  • 最终指南包含 20 条条目:9 条方法学考虑和 11 条报告考虑。

关键数值与推荐

  • 第一轮专家对条目重要性评分 4 或 5 的比例范围为 64-100%(均值 86.5%)。
  • 第二轮专家将条目评为必需的比例范围为 33-100%(均值 78.7%)。

临床怎么用

  • 在临床试验导入期设计、实施和报告时,可参照 MARMAR 的 9 条方法学和 11 条报告条目,规范用药依从性的测量、分析与报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trial run-in phases are sometimes used to select participants into clinical trials who are most likely to remain adherent to study medications. The study designs and data analysis methods employed lack clear regulatory guidance while reporting is not consistent or transparent. This study aims to develop a consensus guideline for the Measurement, Analysis, and Reporting of Medication Adherence during the Run-in phase (MARMAR) of clinical trials. METHODS: Initial "items" (specific statements relating to the measurement, analysis, and reporting of medication adherence during trial run-in phases) were generated following a systematic review of trial run-in phases. Items were split into 2 domains (methods and reporting), refined through a pilot exercise and subsequently evaluated using a two-round modified Delphi survey of international experts in medication adherence and clinical trials. Participants were recruited via e-mailing lists. In survey round one, respondents rated the importance of items across a scale labelled strongly agree to strongly disagree and provided free-text comments. In survey round two, respondents categorised items as essential or desirable and suggested alternative wording. A final consensus meeting of the research team was held to finalise the guideline. Guideline development was endorsed by the International Society for Medication Adherence (ESPACOMP) and registered with EQUATOR. RESULTS: In round one, 49 respondents rated 29 items, with 64-100% (mean 86.5%) of experts scoring an item 4 or 5. Consensus was reached for 28 items, and 226 free-text comments led to merging overlapping items. In round two, 27 respondents rated 20 revised items, with 33-100% (mean 78.7%) of experts judging them essential and providing 66 free-text comments. The final MARMAR guideline comprises 20 items: 9 methodological and 11 reporting considerations for medication adherence during trial run-in phases. CONCLUSION: The MARMAR guideline provides the first structured, consensus-based guideline specifically focused on medication adherence during trial run-in phases. By supporting more transparent and rigorous measurement, analysis and reporting, it should serve to improve the quality of future trial run-in phases.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Davies N, Vrijens B, Wright DFB, et al. Guideline for the Measurement, Analysis and Reporting of Medication Adherence during the Run-in phase of clinical trials (MARMAR). Trials. 2026. PMID: 41987203. doi:10.1186/s13063-026-09717-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。